WSE has been studied to treat anxiety and depression in separate clinical trials. Negative symptoms of schizophrenia are usually enduring. As antipsychotic drugs have limitations this seems like a viable augmentation strategy especially due to a milder side-effect profile. Note that it did not benefit positive symptoms. Replication studies in a larger sample size are needed. Clinicians have commonly used lithium, divalproex, or another antipsychotic to augment in this group of patients but the data is limited. Clozapine is an underutilized option that should be considered but has limitations of side-effects and needs for monitoring.
It would currently be considered off-label as it is not FDA approved. This treatment could complement antipsychotics as they are effective against positive symptoms and WSE is effective against negative symptoms. Clinicians may choose to add WSE as available at amazon (Swanson Sensoril Anti-Stress Nutraceutical 120 mg capsules) as the Ashwagandha standardized extract. There is now an increasing trend to test nutraceuticals using randomized clinical trials.